Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Morningside Invests in Aduro Biotech, a US Cancer Immunotherapy Co.

publication date: Apr 20, 2011
Morningside Ventures, the Hong Kong venture capital company, participated in the $19.25 million second funding round of Aduro BioTech of Berkeley, California. Aduro uses listeria bacteria as the basis for new vaccines, which it is developing to fight cancer and infectious diseases. Morningside's portfolio of life science investments numbers 36 companies, including ten ventures that are headquartered or have some of their operations in China (including one in Hong Kong). More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital